{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HSCT&page=15",
    "query": {
      "intervention": "HSCT",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 2869,
    "total_pages": 287,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HSCT&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HSCT&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T12:21:13.422Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01885897",
      "title": "IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia (AML)",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Myelodysplastic Syndromes (MDS)",
        "Lymphoma",
        "Myeloma",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Chronic Myelogenous Leukemia (CML)"
      ],
      "interventions": [
        {
          "name": "ALT-803",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2013-11-11",
      "completion_date": "2020-07",
      "has_results": true,
      "last_update_posted_date": "2020-08-12",
      "last_synced_at": "2026-10-23T12:21:13.422Z",
      "location_count": 3,
      "location_summary": "Minneapolis, Minnesota • St Louis, Missouri • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01885897"
    },
    {
      "nct_id": "NCT00003954",
      "title": "Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Refractory Multiple Myeloma",
        "Stage I Multiple Myeloma",
        "Stage II Multiple Myeloma",
        "Stage III Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "autologous bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "1999-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-02-06",
      "last_synced_at": "2026-10-23T12:21:13.422Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Denver, Colorado • Seattle, Washington",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003954"
    },
    {
      "nct_id": "NCT03259503",
      "title": "Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent T-Cell Non-Hodgkin Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Hodgkin Lymphoma",
        "Refractory T-Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Pharmacokinetic Study",
          "type": "OTHER"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2019-09-13",
      "completion_date": "2025-11-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-23T12:21:13.422Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03259503"
    },
    {
      "nct_id": "NCT00619879",
      "title": "Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leukemia, Myelogenous, Chronic",
        "Leukemia, Lymphoblastic, Acute",
        "Leukemia, Myelogenous, Acute",
        "Myeloproliferative-Myelodysplastic Diseases",
        "Lymphoma, Malignant"
      ],
      "interventions": [
        {
          "name": "Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients",
          "type": "DRUG"
        },
        {
          "name": "Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies",
          "type": "DRUG"
        },
        {
          "name": "Hematopoietic Progenitor Cell Transplantation (HPCT)",
          "type": "OTHER"
        },
        {
          "name": "CNS radiation treatment for ALL with prior CNS disease patients",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 81,
      "start_date": "2007-03-26",
      "completion_date": "2019-02-07",
      "has_results": false,
      "last_update_posted_date": "2025-03-07",
      "last_synced_at": "2026-10-23T12:21:13.422Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00619879"
    },
    {
      "nct_id": "NCT02996773",
      "title": "Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myelogenous Leukemia",
        "Myelodysplastic Syndromes",
        "Chronic Myelogenous Leukemia",
        "Lymphoma,Non-Hodgkin",
        "Lymphoma, Hodgkin",
        "Lymphoma, Follicular",
        "Marginal Zone Lymphoma",
        "Large Cell Lymphoma",
        "Mantle-Cell Lymphoma",
        "Gray Zone Lymphoma",
        "Burkitt Lymphoma",
        "High Risk Undifferentiated Acute Leukemia"
      ],
      "interventions": [
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "4 Years to 30 Years"
      },
      "enrollment_count": 50,
      "start_date": "2016-11-29",
      "completion_date": "2025-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-10-23T12:21:13.422Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02996773"
    },
    {
      "nct_id": "NCT04083170",
      "title": "Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Erythroid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Acute Megakaryoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "HIV Infection",
        "Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome With Excess Blasts",
        "Non-Hodgkin Lymphoma",
        "Refractory Anemia"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Umbilical Cord Blood Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Dilanubicel",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "6 Months to 65 Years"
      },
      "enrollment_count": 1,
      "start_date": "2022-10-06",
      "completion_date": "2022-11-30",
      "has_results": true,
      "last_update_posted_date": "2025-01-01",
      "last_synced_at": "2026-10-23T12:21:13.422Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04083170"
    },
    {
      "nct_id": "NCT02065596",
      "title": "Hematopoietic Stem Cell Transplant for Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Sickle Cell Anemia",
        "SCD"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Hematopoietic Stem Cell Transplant (HSCT)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 4,
      "start_date": "2015-10-19",
      "completion_date": "2023-02-17",
      "has_results": false,
      "last_update_posted_date": "2024-04-29",
      "last_synced_at": "2026-10-23T12:21:13.422Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02065596"
    },
    {
      "nct_id": "NCT00600353",
      "title": "Multi-day Doses in Prevention of Nausea and Emesis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloma, Plasma-Cell",
        "Lymphoma, Malignant"
      ],
      "interventions": [
        {
          "name": "Palonosetron",
          "type": "DRUG"
        },
        {
          "name": "Aprepitant",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2007-10",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-09",
      "last_synced_at": "2026-10-23T12:21:13.422Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00600353"
    },
    {
      "nct_id": "NCT04995653",
      "title": "A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Stem Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Vancomycin Pre-Treatment",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin Placebo",
          "type": "DRUG"
        },
        {
          "name": "SER-155",
          "type": "DRUG"
        },
        {
          "name": "SER-155 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seres Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2021-11-24",
      "completion_date": "2024-07-23",
      "has_results": false,
      "last_update_posted_date": "2024-10-01",
      "last_synced_at": "2026-10-23T12:21:13.422Z",
      "location_count": 13,
      "location_summary": "Gilbert, Arizona • Scottsdale, Arizona • Duarte, California + 10 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Marina del Rey",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04995653"
    },
    {
      "nct_id": "NCT01070797",
      "title": "Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adenovirus Infection",
        "Epstein-Barr Virus Infections",
        "Cytomegalovirus Infections",
        "Stem Cell Transplant"
      ],
      "interventions": [
        {
          "name": "Multi-virus Specific T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 10,
      "start_date": "2011-01",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2014-09-04",
      "last_synced_at": "2026-10-23T12:21:13.422Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01070797"
    }
  ]
}